## MKSI: MKS Inc. - XLK: Technology

### Executive Summary

VALUE thesis: PEG 0.61 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($146.33)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 7 ($1.31M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (+4.0%)
- Blackrock Inc.: 9.1% (-16.3%)
- Price (T.Rowe) Assoc: 5.4% (-12.0%)
- Victory Capital Mana: 5.3% (-7.3%)
- FMR, LLC: 5.1% (-10.1%)

### Key Risks

1. High beta (1.93) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-3.2% 5d) with bearish MACD, trend may be turning.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.61 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.9x). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $10.7B |
| Beta | 1.93 |
| 52W Range | $54.84 - $170.37 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.61 |
| Forward P/E | 18.2 |
| Current P/E | 20.7 |
| YoY Growth | 13.4% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 6.3% to 3.1% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.9pp (needs >4.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.11% (CS: 61) | Neutral |
| RSI_14 | 55.6 | Neutral |
| MACD Histogram | -0.33 | Bearish |
| vs SMA20 | 1.027x | Above |
| vs SMA50 | 1.087x | Above |
| vs SMA200 | 1.490x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $159.31
- **Stop Loss:** $146.33 (8.1% risk)
- **Target:** $185.27 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 77
- **Position Value:** $12,266.87
- **Portfolio %:** 12.27%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-11 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.85 | $1.93 | +4.1% |
| 2025Q2 | $1.64 | $1.77 | +8.1% |
| 2025Q1 | $1.45 | $1.71 | +17.5% |
| 2024Q4 | $1.96 | $2.15 | +10.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*